Abstract: Device and system for exchanging energy and/or data, in particular for localization purposes, with at least one implant and/or at least one organ in a human or animal body and/or a device external to the body, via piezoelectric and/or capacitive transducers.

Abstract: A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a JAK inhibitor or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) has the following formula: It further relates to a pharmaceutical composition including the combination, its use and a pharmaceutical kit having it.

Abstract: The invention is directed to a method of determining properties in a vessel or the heart (V) of a patient. It comprises the steps of placing an element in a vessel or the heart(V) and determining a propulsion force (2) acting on the element. Furthermore, at least one of acceleration (3) and velocity (4) of the element is determined. At least one property of a neighbouring medium of the element is determined based on the propulsion force and at least one of acceleration (3) and velocity (4) of the element.

Abstract: Compounds, pharmaceutical compositions, kits, and methods for treating an inflammatory disease, disorder, or condition. The method includes administering to a patient in need thereof: an effective amount of a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and an effective amount of a S1P receptor modulator or a pharmaceutically acceptable salt thereof, to treat the inflammatory disease, disorder, or condition.

Abstract: The invention relates to insertion instruments (50) for insertion into a cavity, the instrument (50) comprising a flexible tubular sheet (1) having a first annular end (12), a second annular end (13) and a middle section (14) extending between the first annular end (12) and the second annular end (13), a first holding member (24) holding the first annular end (12), wherein an outer tubular outer portion (16) of the middle section (14) extends along an extension direction (D), from the first holding member (24) to a distal tip (17) of the instrument (50), a second holding member (2) holding a tubular inner portion (18) of the middle section (14), wherein the inner portion (18) extends inside the outer tubular outer portion (16) of the sheet (1), from the second holding member (2) to the distal tip (17), the inner portion (18) transiting into the outer portion (16) at the distal tip (17), a passage (19) defined inside the inner tubular inner portion (18) of the sheet (1), which passage (19) extends from the sec

Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.

Abstract: The invention relates to a medical implant (1) comprising a patch (2). The implant is adapted to close a defect (3), preferably a an opening in a ventricular or atrial septum (4). The medical implant (1) comprises at least one mechanical anchor (5). The anchor may comprise a barb (6) and is adapted to pierce the patch (2) and/or biological tissue (4) such as to fix the medical implant (1) to said tissue (4). The medical implant can be deployed by a delivery device (7). The delivery device (7) may comprise a balloon (8?, 8?), preferably at least two balloons (8?, 8?).

Abstract: The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140° C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.

Abstract: The present invention relates to a medical device (10), preferably a micro robot for application inside a body, preferably for application inside a human body (2). The medical device (10) includes a body part (11) and a tail part (12). A controlling line (13) is attached to the tail part (12). The controlling line (13) has a tensile strength sufficient to pull back the device from a target location and/or control its velocity and column strength not sufficient to push the medical device (10).

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.

Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w??(I), wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its long-term consequences. The uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.

Abstract: The present invention relates to a compound represented by the following formula (I): A[B—(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 to 6. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of such compounds in cosmetic and therapeutic applications. The invention also relates to the use of such compounds for reducing photodegradation and/or photoinstability of pharmaceuticals and cosmetics. The invention further relates to a material comprising a support and such a compound adhered to said support.

Abstract: The invention relates to an endoprosthesis (1), in particular a vascular stent or a heart stent, comprising at least one body (3) part. At least one area (5,6) of an outer surface, preferably the whole outer surface, of the at least one body part (3) is provided with thrombogenic fibers (2). The invention further relates to methods of manufacturing endoprostheses (1).

Abstract: The invention relates to a medical implant (1) that is adapted to repair or close defect (D), in particular an opening in a ventricular, atrial, or septal wall (W). The medical implant (1) may, in particular, be a patch. It comprises an adhesive composition (6). It further comprises two states, wherein in the first state, the medical implant (1) can be deployed to an implant site while the adhesive composition (6) is inactive. It can be brought into a second state by an activation mechanism. The adhesive composition (6), in the second state, is curable by a curing mechanism.

Abstract: The invention relates to medical implant (1) that is adapted to close a defect (D) or a cavity, preferably a defect in an atrial or septal wall (W) or a left atrial appendage. The implant (1) comprises an occlusion device (6) and has two states. It is adapted to, in a first state, be deployed to a defect site (D), where it can be brought into a second state by an activation mechanism. It is adapted to close said defect (D) in said second state.

Abstract: The invention is directed to a method of determining properties in a vessel or the heart (V) of a patient. It comprises the steps of placing an element in a vessel or the heart(V) and determining a propulsion force (2) acting on the element. Furthermore, at least one of acceleration (3) and velocity (4) of the element is determined. At least one property of a neighbouring medium of the element is determined based on the propulsion force and at least one of acceleration (3) and velocity (4) of the element.

Abstract: The invention relates to a positioning device (1) comprising a distal part (8) that is adapted to be delivered through a defect, preferably an opening in a ventricular or atrial septum. It comprises a mechanism to selectively expand the distal part (8), such that before expansion, it can be deployed through said defect, and upon expansion, is mechanically prevented from being retracted through the same defect. Thus, the positioning device (1) is temporarily engaged at the defect site.

Abstract: The present invention relates to a set of particles comprising at least one bioadhesive particle of formula (I): {A-[(B)n-C]m}.X??(I), in which A represents a polymer core, B represents a linear linker, C represents a functional group, n is 0 or 1, and m is an integer from 1 to 1025, and where said bioadhesive particle encapsulates or is attached to at least one active agent X. It also relates to a composition comprising the same and, more particularly, to a cosmetic or a sunscreen composition. It also relates to the use of the set of particles in medicine, in particular for treating and/or preventing skin, mucosa, or eye cornea diseases or conditions.

Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.